The risk of breast implant-associated anaplastic large cell lymphoma may be higher than previously reported for women who receive textured implants, according to researchers.
The purpose of this study is to assess the safety, tolerability, and antitumor activity, as well as recommended dose of brentuximab vedotin in combination with a multiagent chemotherapy regimen.
A retrospective study sought to determine the risk factors for thromboembolism in patients with acute leukemia or lymphoma.
Ibrutinib may impair natural killer cell cytotoxic activity, potentially through off-target inhibition of IL-2–inducible kinase (ITK), an in vitro study suggests.
Though the primary survival endpoints were not met in this study, younger patients experienced improved outcomes with ibrutinib.
Researchers sought to compare the cost effectiveness of the treatments used for patients with relapsed/refractory DLBCL.
Early failure after treatment, old age, and treatment regimens not including stem cell transplantation were associated with poorer survival.
“Nonrelapse mortality needs to be defined prospectively for all ongoing CAR-T studies,” said the researchers.
Additional research is needed on the best dose schedule for the drug.
Patients receiving rituximab maintenance and undergoing observation demonstrated similar rates of overall and disease-free survival.
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
The FDA has approved Revlimid (lenalidomide; Celgene) in combination with a rituximab product (R²) for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
Follicular lymphoma manifesting with skin involvement only is considered to be a more aggressive disease than PCFCL.
A second-generation anti-CD19 chimeric antigen receptor T-cell therapy showed clinical benefit and low toxicity in a phase 1 trial for B-cell lymphoma.
The detection of extranodal, soft tissue, bone, and spleen involvement at baseline predicted poor survival outcomes in patients with untreated follicular lymphoma.
For patients with advanced-stage Hodgkin lymphoma (HL) with large tumors, limited evidence suggests that consolidation radiotherapy (RT) after chemotherapy may prolong progression-free survival.
Results of a retrospective study of the treatment patterns and outcomes of a cohort of children and young adults with relapsed/refractory Hodgkin lymphoma showed high 5-year rates of freedom from local failure and overall survival (OS) in patients receiving moderate-dose salvage radiation therapy.
The “Kick & Kill” platform is designed to treat viral-associated cancers and other serious diseases.
The presence of rheumatologic conditions was also associated with variations in cancer site for both diffuse large B-cell lymphoma and marginal zone lymphoma.
Follicular lymphoma is classified into 3 histologic grades on the basis of the number of centroblasts per high-power field.